TaiRx, Inc. (TPEX:6580)
Taiwan · Delayed Price · Currency is TWD 15.00
-1.00 (-6.25%)
Sep 15, 2026, 1:58 PM CST
TaiRx Revenue
TaiRx had revenue of 9.07M TWD in the half year ending June 30, 2026, with 3,323.77% growth. This brings the company's revenue in the last twelve months to 29.44M, up 90.44% year-over-year. In the year 2025, TaiRx had annual revenue of 27.88M with 239.03% growth.
Revenue (ttm)
29.44M
Revenue Growth
+90.44%
P/S Ratio
28.26
Revenue / Employee
n/a
Employees
n/a
Market Cap
832.08M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 27.88M | 19.65M | 239.03% |
| Dec 31, 2024 | 8.22M | 3.14M | 61.79% |
| Dec 31, 2023 | 5.08M | -1.84M | -26.59% |
| Dec 31, 2022 | 6.92M | 1.78M | 34.66% |
| Dec 31, 2021 | 5.14M | 1.78M | 53.05% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Synbio Tech | 1.01B |
| GenMont Biotech Incorporation | 382.11M |
| Abnova (Taiwan) | 345.45M |
| NeoCore Technology | 277.54M |
| G&E Herbal Biotechnology | 215.61M |
| Enimmune | 53.45M |